C4 Therapeutics to Participate in Upcoming Conferences

About this update from C4 Therapeutics, Inc.

WATERTOWN, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in the upcoming conferences. TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA 2026 Jefferies Global Healthcare Conference Goldman Sachs 47th Annual Global Healthcare Conference The live webcasts will be available on the Investors section of the company’s website at www.c4therapeutics.com . Archived replays of the webcasts will be available for approximately 90 days following the events. About C4 Therapeutics C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO ®  platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit  www.c4therapeutics.com . Contacts: Investors: Courtney Solberg Associate Director, Investor Relations [email protected] Leah Gibson Vice President, Investor Relations & Communications [email protected] Media: Loraine Spreen Senior Director, Corporate Communications & Patient Advocacy [email protected]

View stock analysis, news, and events for C4 Therapeutics, Inc.